Your browser is no longer supported. Please, upgrade your browser.
Atea Pharmaceuticals, Inc.
Index- P/E98.97 EPS (ttm)0.25 Insider Own18.48% Shs Outstand82.58M Perf Week-0.28%
Market Cap2.11B Forward P/E2.08 EPS next Y12.06 Insider Trans0.00% Shs Float67.44M Perf Month16.57%
Income23.80M PEG- EPS next Q0.01 Inst Own63.50% Short Float10.49% Perf Quarter1.34%
Sales114.60M P/S18.38 EPS this Y23.60% Inst Trans0.00% Short Ratio5.27 Perf Half Y-65.70%
Book/sh7.10 P/B3.53 EPS next Y2336.36% ROA4.90% Target Price35.00 Perf Year-
Cash/sh9.91 P/C2.53 EPS next 5Y- ROE9.60% 52W Range18.72 - 94.17 Perf YTD-40.07%
Dividend- P/FCF- EPS past 5Y- ROI-2.00% 52W High-73.41% Beta-
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low33.76% ATR1.66
Employees42 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)53.71 Volatility5.30% 6.87%
OptionableYes Debt/Eq0.00 EPS Q/Q797.90% Profit Margin20.70% Rel Volume0.48 Prev Close24.35
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout0.00% Avg Volume1.34M Price25.04
Recom1.70 SMA205.33% SMA508.39% SMA200-40.54% Volume641,793 Change2.83%
Nov-25-20Initiated Evercore ISI Outperform
Nov-24-20Initiated William Blair Outperform $60
Nov-24-20Initiated Morgan Stanley Overweight $49
Nov-24-20Initiated JP Morgan Overweight $45
Jul-12-21 07:00AM  
Jun-30-21 11:11AM  
Jun-16-21 09:26AM  
Jun-15-21 07:00AM  
May-26-21 07:00AM  
May-25-21 12:41AM  
May-20-21 07:00AM  
May-15-21 03:26AM  
May-13-21 04:05PM  
May-06-21 07:00AM  
Apr-29-21 06:44AM  
Apr-22-21 06:25AM  
Apr-21-21 05:15AM  
Apr-16-21 06:49AM  
Apr-14-21 09:40AM  
Apr-08-21 01:24AM  
Mar-31-21 02:00AM  
Mar-30-21 04:01PM  
Mar-23-21 07:00AM  
Mar-06-21 07:00AM  
Feb-19-21 08:30AM  
Feb-09-21 08:09AM  
Feb-08-21 04:01PM  
Feb-04-21 07:00AM  
Jan-30-21 01:30AM  
Jan-26-21 06:20AM  
Jan-19-21 07:00AM  
Dec-21-20 08:48AM  
Dec-18-20 08:00AM  
Nov-25-20 07:00AM  
Nov-20-20 07:54PM  
Nov-06-20 08:00AM  
Nov-03-20 04:01PM  
Nov-01-20 09:29PM  
Oct-29-20 08:00PM  
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.